A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer

Bilgin B., Sendur M. A. N., Dede D. S., Akinci M. B., Yalcin B.

CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.9, pp.1559-1569, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 33 Issue: 9
  • Publication Date: 2017
  • Doi Number: 10.1080/03007995.2017.1348344
  • Journal Name: CURRENT MEDICAL RESEARCH AND OPINION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1559-1569
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Background: Resistance to endocrine treatment generally occurs over time, especially in the metastatic stage. In this paper, we aimed to review the mechanisms of cyclin-dependent kinase (CDK) 4/6 inhibition and clinical usage of new agents in the light of recent literature updates.